Eric Benevich
Chief Commercial Officer at Neurocrine Biosciences Inc (NBIX)
Eric Benevich has filed 36 insider reports with the SEC since January 2021, as chief Commercial Officer at Neurocrine Biosciences Inc (NBIX) and director at aTYR PHARMA INC (ATYR). In the last 12 months Eric Benevich sold $333K of stock on the open market. The latest filing, on September 15, 2026, reports grant or award and shares withheld for taxes or exercise price at Neurocrine Biosciences Inc (NBIX).
- Filings
- 36
- Companies
- 2
- Bought on market
- None
- Sold on market
- $39.9M
Companies where Eric Benevich is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Chief Commercial Officer | 67,297 | $39.9M | $162.86 | Sep 15, 2026 | |||
| Directorsince December 2024 | $4.08 | May 13, 2026 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Sep 11, 2026NBIXChief Commercial Officer Benevich Eric was granted 6,275 shares and covered exercise/tax liability with 3,386 shares, increasing direct ownership by 4% to 67,297 units (tax liability)Form 4Grant or awardShares withheld for taxes or exercise price
- Sep 9, 2026-$333KNBIXChief Commercial Officer Benevich Eric sold $333,030 worth of shares (2,154 units at $154.61) as part of a pre-agreed trading plan and exercised 3,194 shares at a strike of $43.24, increasing direct ownership by 2% to 64,408 unitsForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- May 11, 2026ATYRSEC Form 4 filed by Director Benevich EricForm 4Grant or award
- Feb 13, 2026NBIXChief Commercial Officer Benevich Eric converted options into 6,049 shares, covered exercise/tax liability with 12,227 shares and was granted 16,613 shares, increasing direct ownership by 20% to 63,190 unitsForm 4Grant or awardShares withheld for taxes or exercise priceExercise or conversion of a derivative
- Jan 31, 2026NBIXChief Commercial Officer Benevich Eric converted options into 2,294 shares and covered exercise/tax liability with 1,292 shares, increasing direct ownership by 2% to 52,755 unitsForm 4Shares withheld for taxes or exercise priceExercise or conversion of a derivative
- Nov 28, 2025NBIXAmendment: Chief Commercial Officer Benevich Eric exercised 12,830 shares at a strike of $35.99, increasing direct ownership by 29% to 57,723 unitsForm 4Exercise or conversion of a derivative
- Nov 28, 2025~$905KNBIXEric Benevich plans to sell 5,970 shares (~$905K)Form 144Planned sale10b5-1 plan
- May 1, 2025ATYRSEC Form 4 filed by Director Benevich EricForm 4Grant or award
- Feb 13, 2025-$251KNBIXChief Commercial Officer Benevich Eric converted options into 4,044 shares and sold $251,428 worth of shares (2,154 units at $116.73), increasing direct ownership by 4% to 44,689 unitsForm 4Grant or awardExercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Feb 10, 2025-$116KNBIXChief Commercial Officer Benevich Eric sold $115,940 worth of shares (980 units at $118.31) and converted options into 1,860 shares, increasing direct ownership by 2% to 42,799 unitsForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Jan 31, 2025-$185KNBIXChief Commercial Officer Benevich Eric converted options into 2,294 shares and sold $184,599 worth of shares (1,207 units at $152.94), increasing direct ownership by 3% to 41,919 unitsForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Dec 10, 2024ATYRSEC Form 4 filed by Director Benevich EricForm 4Grant or award
- Dec 10, 2024ATYREric Benevich became an insiderForm 3New insider
- Apr 15, 2024-$2.64MNBIXBenevich Eric exercised 19,818 shares at a strike of $81.21 and sold $2,643,020 worth of shares (19,818 units at $133.36)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Mar 14, 2024-$10.5MNBIXBenevich Eric sold $10,453,418 worth of shares (75,000 units at $139.38) and exercised 75,000 shares at a strike of $80.90Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Mar 14, 2024~$10.6MNBIXEric Benevich plans to sell 75,000 shares (~$10.6M)Form 144Planned sale10b5-1 plan
- Feb 28, 2024-$10.1MNBIXBenevich Eric exercised 75,000 shares at a strike of $53.67 and sold $10,101,608 worth of shares (75,000 units at $134.69)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Feb 13, 2024-$146KNBIXBenevich Eric sold $146,050 worth of shares (1,098 units at $133.01), decreasing direct ownership by 3% to 40,616 unitsForm 4Grant or awardOpen-market sale10b5-1 plan
- Feb 8, 2024-$313KNBIXBenevich Eric sold $313,419 worth of shares (2,260 units at $138.68), decreasing direct ownership by 1.00% to 39,631 unitsForm 4Open-market sale10b5-1 plan
- Jan 31, 2024-$170KNBIXBenevich Eric sold $169,927 worth of shares (1,207 units at $140.78), decreasing direct ownership by 3% to 37,601 unitsForm 4Open-market sale10b5-1 plan
- Aug 21, 2023-$172KNBIXSEC Form 4: Benevich Eric sold $171,836 worth of shares (1,600 units at $107.40), decreasing direct ownership by 4% to 36,436 unitsForm 4Open-market sale10b5-1 plan
- May 11, 2023NBIXSEC Form 4 filed by Benevich Eric (Amendment)Form 4
- May 11, 2023NBIXSEC Form 4 filed by Benevich Eric (Amendment)Form 4
- Feb 13, 2023NBIXSEC Form 4 filed by Benevich EricForm 4Grant or award
- Feb 8, 2023-$2.02MNBIXSEC Form 4: Benevich Eric sold $2,018,105 worth of shares (19,650 units at $102.70) as part of a pre-agreed trading plan, increasing direct ownership by 79% to 34,381 units (withholding tax)Form 4Open-market sale10b5-1 plan
- Jan 31, 2023-$133KNBIXSEC Form 4: Benevich Eric sold $132,710 worth of shares (1,207 units at $109.95) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 16,729 units (tax withholding)Form 4Open-market sale10b5-1 plan
- Jan 6, 2023-$50KNBIXSEC Form 4: Benevich Eric exercised 400 shares at a strike of $43.24 and sold $50,000 worth of shares (400 units at $125.00) as part of a pre-agreed trading planForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Nov 30, 2022-$6.3MNBIXSEC Form 4: Benevich Eric exercised 50,000 shares at a strike of $41.47 and sold $6,295,085 worth of shares (50,000 units at $125.90) as part of a pre-agreed trading planForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Nov 10, 2022-$3.09MNBIXSEC Form 4: Benevich Eric exercised 24,693 shares at a strike of $41.78 and sold $3,094,856 worth of shares (24,693 units at $125.33) as part of a pre-agreed trading planForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Nov 3, 2022-$1.17MNBIXSEC Form 4: Benevich Eric exercised 9,368 shares at a strike of $41.78 and sold $1,171,183 worth of shares (9,368 units at $125.02) as part of a pre-agreed trading planForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Oct 17, 2022-$550KNBIXSEC Form 4: Benevich Eric sold $549,682 worth of shares (4,960 units at $110.82) as part of a pre-agreed trading plan, decreasing direct ownership by 24% to 15,643 unitsForm 4Open-market sale10b5-1 plan
- Feb 8, 2022-$411KNBIXSEC Form 4: Benevich Eric sold $410,821 worth of shares (5,099 units at $80.57) as part of a pre-agreed trading plan, increasing direct ownership by 18% to 20,338 units (withholding tax)Form 4Open-market sale10b5-1 plan
- Jan 31, 2022NBIXSEC Form 4 filed by Benevich EricForm 4Grant or award
- Feb 8, 2021NBIXSEC Form 4 filed by Eric BenevichForm 4Grant or award
- Feb 8, 2021-$591KNBIXSEC Form 4: Eric Benevich sold $591,089 worth of Common Stock (5,079 units at $116.38), increasing ownership by 22% to 21,099 unitsForm 4Grant or awardOpen-market sale10b5-1 plan
- Jan 26, 2021-$657KNBIXSEC Form 4: Eric Benevich exercised 3,777 units of Common Stock at a strike of $41.78 and sold $657,371 worth of Common Stock (5,477 units at $120.02), decreasing ownership by 10% to 15,705 unitsForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
Compare Eric Benevich with
- Eric Benevich vs Eiry Roberts1 shared
- Eric Benevich vs George J Morrow1 shared
- Eric Benevich vs Kyle Gano1 shared
- Eric Benevich vs Brandon Yaras1 shared
- Eric Benevich vs Jude Onyia1 shared
- Eric Benevich vs Darin Lippoldt1 shared
Other insiders at the same companies
- Eiry RobertsNBIX
- George J MorrowNBIX
- Kyle GanoNBIX
- Brandon YarasATYR
- Jude OnyiaNBIX
- Darin LippoldtNBIX
- Sanjay Chandru KeswaniNBIX
- Kevin Charles GormanNBIX
- Ingrid DelaetNBIX
- Julie CookeNBIX
- David W. BoyerNBIX
- Matt AbernethyNBIX
- Stephen A SherwinNBIX
- Leslie V NorwalkNBIX
- Richard F PopsNBIX
- Gary A LyonsNBIX
Questions about Eric Benevich
- What is Eric Benevich's role at Neurocrine Biosciences Inc?
- Eric Benevich reports to the SEC as chief Commercial Officer at Neurocrine Biosciences Inc (NBIX), according to the latest filing on September 15, 2026. Eric Benevich has also filed as director at aTYR PHARMA INC (ATYR).
- How many shares does Eric Benevich own?
- After the latest filing that states it, Eric Benevich directly owned 67,297 shares of Neurocrine Biosciences Inc (NBIX). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Eric Benevich bought or sold stock recently?
- The most recent open-market sale was on September 9, 2026: sold 2,154 shares of Neurocrine Biosciences Inc (NBIX) for $333K at an average of $154.61.
- How do I get alerts when Eric Benevich files?
- Follow Eric Benevich on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale. Eric Benevich filed 2 times in the last 90 days.
From SEC Forms 3, 4, 5 and 144 filed by Eric Benevich (SEC CIK 0001643653). Totals count each trade once, skipping amendments whose original is on file, from Jan 28, 2021 on. View on SEC EDGAR